Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22811Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ioannidis, J. P. | en |
| dc.date.accessioned | 2015-11-24T19:27:25Z | - |
| dc.date.available | 2015-11-24T19:27:25Z | - |
| dc.identifier.issn | 1538-3598 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22811 | - |
| dc.rights | Default Licence | - |
| dc.subject | *Bibliometrics | en |
| dc.subject | *Clinical Trials as Topic | en |
| dc.subject | Evidence-Based Medicine | en |
| dc.subject | *Periodicals as Topic | en |
| dc.subject | Publishing | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Research Design | en |
| dc.title | Contradicted and initially stronger effects in highly cited clinical research | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1001/jama.294.2.218 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16014596 | - |
| heal.identifier.secondary | http://jama.ama-assn.org/content/294/2/218.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | CONTEXT: Controversy and uncertainty ensue when the results of clinical research on the effectiveness of interventions are subsequently contradicted. Controversies are most prominent when high-impact research is involved. OBJECTIVES: To understand how frequently highly cited studies are contradicted or find effects that are stronger than in other similar studies and to discern whether specific characteristics are associated with such refutation over time. DESIGN: All original clinical research studies published in 3 major general clinical journals or high-impact-factor specialty journals in 1990-2003 and cited more than 1000 times in the literature were examined. MAIN OUTCOME MEASURE: The results of highly cited articles were compared against subsequent studies of comparable or larger sample size and similar or better controlled designs. The same analysis was also performed comparatively for matched studies that were not so highly cited. RESULTS: Of 49 highly cited original clinical research studies, 45 claimed that the intervention was effective. Of these, 7 (16%) were contradicted by subsequent studies, 7 others (16%) had found effects that were stronger than those of subsequent studies, 20 (44%) were replicated, and 11 (24%) remained largely unchallenged. Five of 6 highly-cited nonrandomized studies had been contradicted or had found stronger effects vs 9 of 39 randomized controlled trials (P = .008). Among randomized trials, studies with contradicted or stronger effects were smaller (P = .009) than replicated or unchallenged studies although there was no statistically significant difference in their early or overall citation impact. Matched control studies did not have a significantly different share of refuted results than highly cited studies, but they included more studies with "negative" results. CONCLUSIONS: Contradiction and initially stronger effects are not unusual in highly cited research of clinical interventions and their outcomes. The extent to which high citations may provoke contradictions and vice versa needs more study. Controversies are most common with highly cited nonrandomized studies, but even the most highly cited randomized trials may be challenged and refuted over time, especially small ones. | en |
| heal.journalName | JAMA | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Ioannidis-2005-Contradicted and ini.pdf | 150.73 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
